Perinatal HIV-1 transmission -: Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort

被引:201
作者
Mandelbrot, L
Le Chenadec, J
Berrebi, A
Bongain, M
Bénifla, JL
Delfraissy, JF
Blanche, S
Mayaux, MJ
机构
[1] Hop Cochin Port Royal, Serv Gynecol Obstet 1, F-75014 Paris, France
[2] INSERM, U149, Paris, France
[3] INSERM, U292, Le Kremlin Bicetre, France
[4] Hop La Grave, Serv Gynecol Obstet, Toulouse, France
[5] Hop Archet 2, Serv Gynecol Obstet, Nice, France
[6] Hop Bichat Claude Bernard, Serv Gynecol Obstet, F-75877 Paris, France
[7] Hop Kremlin Bicetre, Serv Med Interne, Le Kremlin Bicetre, France
[8] Hop Necker Enfants Malad, Serv Pediat, Paris, France
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1998年 / 280卷 / 01期
关键词
D O I
10.1001/jama.280.1.55
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context.-It is unclear whether elective cesarean delivery may have a protective effect against the transmission of human immunodeficiency virus 1 (HIV-1). Objective.-To investigate whether mode of delivery has an impact on perinatal HIV-1 transmission in the presence of zidovudine prophylaxis. Design.-A prospective cohort study. Setting.-The 85 perinatal centers in the French Perinatal Cohort, from 1985 to 1996. Patients.-A total of 2834 singleton children born to mothers with HIV-1 infection. Main Outcome Measure.-Human immunodeficiency virus 1 infection of the infant. Results.-No zidovudine was used in 1917 pregnancies and zidovudine prophylaxis was used in 902 pregnancies. Cesarean deliveries were performed in 10.9% on an emergent basis and in 8.3% electively, prior to labor or membrane rupture. In 1917 mothers who did not receive zidovudine, of 1877 with information on mode of delivery, 17.2% transmitted HIV-1 to their child. Risk factors statistically significantly associated with transmission were maternal p24 antigenemia, cervicovaginal infections during pregnancy, amniotic fluid color, and rupture of membranes 4 hours or more before delivery. Mode of delivery was not related to transmission. in 902 mothers receiving zidovudine, transmission was 6.4% in 872 with information on mode of delivery, and elective cesarean delivery (n = 133) was associated with a lower transmission rate than emergent cesarean or vaginal delivery (0.8%, 11.4%, and 6.6%, respectively; P=.002). In a multivariate analysis of all mother-child pairs, including obstetrical risk factors, maternal p24 antigenemia, and zidovudine prophylaxis, interaction between mode of delivery and zidovudine prophylaxis was significant (P=.007). In the multivariate analysis of pregnancies with zidovudine prophylaxis, factors related to transmission rate were maternal p24 antigenemia, amniotic fluid color, and mode of delivery. Adjusted odds ratios (95% confidence intervals) were 1.6 (0.7-3.6) for emergent cesarean delivery and 0.2 (0.0-0.9) for elective cesarean delivery (P =.04) in comparison with vaginal delivery. Conclusions.-We observed an interaction between zidovudine prophylaxis and elective cesarean delivery in decreasing transmission of HIV-1 from mother to child. This observation may have clinical implications for prevention.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 40 条
  • [1] [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1
  • [2] Does umbilical cord blood polymerase chain reaction positivity indicate in utero (pre-labor) HIV infection?
    Biggar, RJ
    Mtimavalye, L
    Justesen, A
    Broadhead, R
    Miley, W
    Waters, D
    Goedert, JJ
    Chiphangwi, JD
    Taha, TE
    Miotti, PG
    [J]. AIDS, 1997, 11 (11) : 1375 - 1382
  • [3] A PROSPECTIVE-STUDY OF INFANTS BORN TO WOMEN SEROPOSITIVE FOR HUMAN IMMUNODEFICIENCY VIRUS TYPE-1
    BLANCHE, S
    ROUZIOUX, C
    MOSCATO, MLG
    VEBER, F
    MAYAUX, MJ
    JACOMET, C
    TRICOIRE, J
    DEVILLE, A
    VIAL, M
    FIRTION, G
    DECREPY, A
    DOUARD, D
    ROBIN, M
    COURPOTIN, C
    CIRARUVIGNERON, N
    LEDEIST, F
    GRISCELLI, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (25) : 1643 - 1648
  • [4] FACTORS PREDICTIVE OF MATERNAL-FETAL TRANSMISSION OF HIV-1 - PRELIMINARY-ANALYSIS OF ZIDOVUDINE GIVEN DURING PREGNANCY AND/OR DELIVERY
    BOYER, PJ
    DILLON, M
    NAVAIE, M
    DEVEIKIS, A
    KELLER, M
    OROURKE, S
    BRYSON, YJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (24): : 1925 - 1930
  • [5] BROSSARD Y, 1995, AIDS, V9, P359, DOI 10.1097/00002030-199509040-00007
  • [6] BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718
  • [7] Bulterys M, 1996, AIDS, V10, P923, DOI 10.1097/00002030-199607000-00019
  • [8] RISK-FACTORS FOR MOTHER-TO-CHILD TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS-1 INFECTION
    BWAYO, J
    TEMMERMAN, M
    NYONGO, AO
    FRANSEN, K
    COPPENS, M
    PIOT, P
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 172 (02) : 700 - 705
  • [9] REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT
    CONNOR, EM
    SPERLING, RS
    GELBER, R
    KISELEV, P
    SCOTT, G
    OSULLIVAN, MJ
    VANDYKE, R
    BEY, M
    SHEARER, W
    JACOBSON, RL
    JIMENEZ, E
    ONEILL, E
    BAZIN, B
    DELFRAISSY, JF
    CULNANE, M
    COOMBS, R
    ELKINS, M
    MOYE, J
    STRATTON, P
    BALSLEY, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) : 1173 - 1180
  • [10] DUNN DT, 1994, J ACQ IMMUN DEF SYND, V7, P1064